What is Zephyr AI?
Zephyr AI is dedicated to transforming precision medicine in oncology and cardiometabolic disease. By integrating proprietary data with advanced artificial intelligence, the company is building the world's most comprehensive healthcare dataset. This unique approach enables the generation of novel, translatable insights, leading to the development of tools and products that support patients, providers, and ongoing research. Zephyr AI's mission-focused team comprises world-class software engineers and biologists leveraging big data and next-generation technology to derive transformational insights and forge enduring partnerships.
How much funding has Zephyr AI raised?
Zephyr AI has raised a total of $189.5M across 3 funding rounds:
Angel/Seed
$18.5M
Series A
$111M
Private Equity
$60M
Angel/Seed (2022): $18.5M with participation from Allen Chao, AME Cloud Ventures, Lerner Group Investments, Boxgroup Ventures, and Medstar Health
Series A (2024): $111M led by Eli Lilly, Revolution Growth, and Epiq Capital Group
Private Equity (2024): $60M supported by Elda River Capital Management and The Pritzker Organization
Key Investors in Zephyr AI
Elda River Capital Management
Elda River Capital Management is a prominent real assets investment firm specializing in energy transition and low carbon infrastructure, having committed over $7.3 billion in capital to various transactions.
AME Cloud Ventures
AME Cloud Ventures is a venture fund focusing on seed to later stage companies that build infrastructure and value chains around data, investing in technology-heavy companies that gather or create unique data.
Eli Lilly
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, manufacturing, and commercialization of prescription medicines, focusing on areas such as diabetes, oncology, and neuroscience.
What's next for Zephyr AI?
The substantial enterprise-level backing and recent strategic investment position Zephyr AI for accelerated growth and market expansion. This capital infusion is anticipated to fuel further development of its AI-driven platform, enhance its data curation capabilities, and broaden its strategic partnerships within the healthcare ecosystem. The company's focus on oncology and cardiometabolic diseases, coupled with its commitment to leveraging big data, suggests a trajectory aimed at becoming a leader in AI-powered medical innovation, potentially leading to further funding rounds or strategic acquisitions as it scales its impact.
See full Zephyr AI company page
